SUO 2024
SUO 2024
SUO 2024: Biomarkers and Clinical Predictors in RCC
- Details
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Kidney Cancer Session II. Dr Mark Ball discussed Biomarkers and Clinical Predictors in Renal Cell Carcinoma (RCC).
SUO 2024: Update on Neoadjuvant Therapy Trials in RCC
- Details
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Kidney Cancer Session II. Dr Naomi Haas presented an update on Neoadjuvant therapy trials in renal cell carcinoma (RCC).
SUO 2024: Sexual Dysfunction and Radical Cystectomy
- Details
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Session II. Dr. Trinity Bivalacqua discussed Sexual Dysfunction and Radical Cystectomy.
SUO 2024: Joseph A Smith, Jr. Mentorship Award Lecture
- Details
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Joseph A Smith, Jr. Mentorship Award Lecture. by Dr. Christopher Kane.
SUO 2024: Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting
- Details
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Session II. Dr. Mamta Parikh discussed Emerging Therapeutics: Combination Therapy in the Neoadjuvant Setting for Bladder Cancer.
SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Salvage Radical Prostatectomy
- Details
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of localized radiorecurrent prostate cancer, and a presentation by Dr. Behfar Ehdaie discussing the role of salvage radical prostatectomy.
SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Salvage Radiotherapy
- Details
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of localized radiorecurrent prostate cancer, and a presentation by Dr. Himanshu Nagar discussing the role of salvage radiotherapy. A solitary loco-regional recurrence on PSMA PET/CT for PSA recurrence is common, seen in 17%-71% of cases after primary radiotherapy:
SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Focal Ablation
- Details
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of localized radiorecurrent prostate cancer, and a presentation by Dr. Kara Watts discussing the role of salvage focal ablation. Currently, ~90-95% of men with biochemical recurrence after radiotherapy are managed with ADT alone.
SUO 2024: Sustainability in Prostate Cancer Care
- Details
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a presentation by Dr. Michael Leapman discussing sustainability in prostate cancer care. Despite increased pledges and targets to address climate change, current policies still leave the world on course for a ~2.7 °C end-of-century global warming above pre-industrial levels—far from the ambitious aim of the Paris Agreement to limit global warming to 1.5 °C:
SUO 2024: Biology of Cancer Metastases
- Details
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a presentation by Dr. Ganesh Palapattu discussing the biology of cancer metastases. Dr. Palapattu started his presentation by emphasizing that the reason we should care about the biology of cancer metastasis is that we may be able to improve risk stratification of localized disease and that we also may be able to improve therapy for advanced disease.
SUO 2024: Game Changing Team Science
- Details
(UroToday.com) At the 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX between December 3rd – 6th, 2024, Dr. Seth Lerner received the prestigious Huggins Medal award from the SUO committee.
SUO 2024: Preventing and Managing Long Term Complications of Radical Cystectomy
- Details
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Session II. Dr. Hadley Wyre discussed how to prevent and manage Long Term Complications of Radical Cystectomy.
SUO 2024: Exploratory Analysis of Post-treatment Outcomes in Patients with Bacillus Calmette-Guerin-unresponsive High-risk, Non-muscle Invasive Bladder Cancer Who Experienced Non-Response to Pembrolizumab Monotherapy in KEYNOTE-057
- Details
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX between December 3rd – 6th, 2024 was host to a bladder cancer poster session. Dr. Roger Li presented the results of an exploratory, ad hoc analysis of the phase II KEYNOTE-057 trial evaluating the post-treatment outcomes of patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk (HR), non-muscle invasive bladder cancer (NMIBC) who experienced a ‘non-response’ to pembrolizumab monotherapy.
SUO 2024: Setting the Stage: Our Current Options for BCG Unresponsive NMIBC
- Details
(UroToday.com) The 2024 SUO annual meeting included a session on BCG unresponsive non muscle invasive bladder cancer (NMIBC), featuring a presentation by Dr. Eugene Pietzak III discussing our current options for BCG unresponsive NMIBC. The BCG unresponsive definition based on expert opinion is as follows:
SUO 2024: Are We Missing Aggressive Cancer with PSA Screening Alone? Biochemical Recurrence After Radical Prostatectomy: Evidence from the STHLM3 Trial
- Details
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a late breaking abstract presentation by Dr. Tobias Nordstrom discussing the STHLM3 trial and biochemical recurrence after radical prostatectomy and whether we are missing aggressive prostate cancer with PSA screening alone.
SUO 2024: Telehealth and Cancer: Public Policy and Future Directions
- Details
(UroToday.com) The 2024 SUO annual meeting included a health services session, featuring a presentation by Dr. Juan Andino discussing public policy and future directions of telehealth and cancer. The workforce challenges in urology today are highlighted by the AUA’s number of urologists practicing per county:
SUO 2024: Novel Approaches to Radiotherapy to Reduce Patient Burden
- Details
(UroToday.com) The 2024 SUO annual meeting included a health services session, featuring a presentation by Dr. Ann Raldow discussing novel approaches to radiotherapy to reduce patient burden. Frequent visits for radiotherapy significantly impact patients’ quality of life due to the associated time burden, loss of income, and increased expenses such as gas and parking costs. Moreover, radiotherapy side effects, including urinary, bowel, and sexual dysfunction, have a lasting effect on long-term well-being. Addressing these challenges and reducing the physical, financial, and emotional burdens of treatment can enhance patient adherence and satisfaction. Importantly, newer radiation approaches are transforming how cancer is treated, leading to shorter, more efficient treatments with fewer side effects and greater convenience for patients.
SUO 2024: Sexual Satisfaction Despite Sexual Dysfunction
- Details
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a presentation by Dr. Daniela Wittmann discussing sexual satisfaction despite sexual dysfunction. Dr. Wittmann started her presentation by highlighting what we most associate with sex: experience of pleasure, feeling of intense satisfaction, intimate connection with a partner, and sharing pleasure. However, she notes that none of these absolutely require intact sexual function.
SUO 2024: Efficacy and Safety of Padeliporfin VTP for Treatment of Low-Grade UTUC: ENLIGHTED Phase 3 study
- Details
(UroToday.com) The 2024 SUO annual meeting included a urothelial carcinoma session, featuring a presentation by Dr. Vitaly Margulis discussing the ENLIGHTED phase 3 study assessing the efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) for the treatment of low-grade upper tract urothelial carcinoma. Padeliporfin VTP is a combination product:
SUO 2024: Clinical Progression of Prostate Cancer from Active Surveillance is Predicted by Decipher® Genomic Classifier Score on Index Biopsy Independent from Risk Assessment by MRI Characteristics
- Details
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX between December 3rd – 6th, 2024 was host to a prostate cancer poster session. Dr. Mark Sultan presented the results of an analysis demonstrating that the Decipher® Genomic Classifier (GC) score on the index biopsy is an independent predictor of clinical progression in active surveillance patients following adjustment for the initial MRI results.